Rivaroxaban is an oral anticoagulant that directly inhibits Factor Xa. By blocking Factor Xa, it reduces the production of thrombin and helps prevent the formation of clots. Rivaroxaban is commonly used to treat and prevent conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke in patients with atrial fibrillation (AF).

The global Rivaroxaban Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

The development of rivaroxaban has progressed significantly since its introduction, driven by its advantages as a direct Factor Xa inhibitor. Initially approved for conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE), rivaroxaban’s development has expanded to include additional indications such as stroke prevention in atrial fibrillation (AF). The focus has been on leveraging its benefits of predictable dosing and minimal need for routine monitoring to address a broader range of thromboembolic conditions, thereby enhancing its therapeutic applications.

Recent trends in rivaroxaban’s development include the exploration of new formulations and dosing regimens. Pharmaceutical companies are investing in research to develop extended-release versions and combination therapies that could provide improved patient compliance and expanded clinical benefits. Additionally, there is ongoing research into its use for other indications, such as in cancer-associated thrombosis, which could further broaden its market applications and solidify its role in modern anticoagulant therapy.

Despite its progress, the development of rivaroxaban faces challenges such as competition from other novel anticoagulants and the need to navigate evolving regulatory requirements and clinical guidelines. Efforts are also underway to enhance its safety profile and address any limitations identified in clinical practice. Continuous innovation and adaptation to new research findings and market needs are crucial for maintaining rivaroxaban’s position and relevance in the rapidly evolving field of anticoagulant therapy.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Rivaroxaban Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rivaroxaban Drugs.

The Rivaroxaban Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Rivaroxaban Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Rivaroxaban Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Rivaroxaban Drugs Market Report

Report Metric	Details
Report Name	Rivaroxaban Drugs Market
Segment by Type	Tablets Oral Suspension
Segment by Application	Deep Vein Thrombosis Pulmonary Embolism Atrial Fibrillation Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Janssen Pharmaceuticals, Bayer, Mylan, Zydus, Lupin, Natco Pharma, Shanghai Huilun Pharmaceutical, Qilu Pharmaceutical, HEC Pharma, Beijing SL Pharmaceutical, Huahai Pharmaceutical, Yangtze River Pharmaceutical, Fujian Cosunter Pharmaceutical, Zhejiang Conba Pharmaceutical, Beijing Baiao Pharmaceutical, Lunan Pharmaceutical, Chia Tai Tianqing Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rivaroxaban Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rivaroxaban Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Rivaroxaban Drugs Market report?

Ans: The main players in the Rivaroxaban Drugs Market are Janssen Pharmaceuticals, Bayer, Mylan, Zydus, Lupin, Natco Pharma, Shanghai Huilun Pharmaceutical, Qilu Pharmaceutical, HEC Pharma, Beijing SL Pharmaceutical, Huahai Pharmaceutical, Yangtze River Pharmaceutical, Fujian Cosunter Pharmaceutical, Zhejiang Conba Pharmaceutical, Beijing Baiao Pharmaceutical, Lunan Pharmaceutical, Chia Tai Tianqing Pharmaceutical

What are the Application segmentation covered in the Rivaroxaban Drugs Market report?

Ans: The Applications covered in the Rivaroxaban Drugs Market report are Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Other

What are the Type segmentation covered in the Rivaroxaban Drugs Market report?

Ans: The Types covered in the Rivaroxaban Drugs Market report are Tablets, Oral Suspension

1 Rivaroxaban Drugs Market Overview

1.1 Product Definition

1.2 Rivaroxaban Drugs by Type

1.2.1 Global Rivaroxaban Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Tablets

1.2.3 Oral Suspension

1.3 Rivaroxaban Drugs by Application

1.3.1 Global Rivaroxaban Drugs Market Value by Application (2024-2030)

1.3.2 Deep Vein Thrombosis

1.3.3 Pulmonary Embolism

1.3.4 Atrial Fibrillation

1.3.5 Other

1.4 Global Rivaroxaban Drugs Market Size Estimates and Forecasts

1.4.1 Global Rivaroxaban Drugs Revenue 2019-2030

1.4.2 Global Rivaroxaban Drugs Sales 2019-2030

1.4.3 Global Rivaroxaban Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Rivaroxaban Drugs Market Competition by Manufacturers

2.1 Global Rivaroxaban Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Rivaroxaban Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Rivaroxaban Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Rivaroxaban Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Rivaroxaban Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Rivaroxaban Drugs, Product Type & Application

2.7 Global Key Manufacturers of Rivaroxaban Drugs, Date of Enter into This Industry

2.8 Global Rivaroxaban Drugs Market Competitive Situation and Trends

2.8.1 Global Rivaroxaban Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Rivaroxaban Drugs Players Market Share by Revenue

2.8.3 Global Rivaroxaban Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Rivaroxaban Drugs Market Scenario by Region

3.1 Global Rivaroxaban Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Rivaroxaban Drugs Sales by Region: 2019-2030

3.2.1 Global Rivaroxaban Drugs Sales by Region: 2019-2024

3.2.2 Global Rivaroxaban Drugs Sales by Region: 2025-2030

3.3 Global Rivaroxaban Drugs Revenue by Region: 2019-2030

3.3.1 Global Rivaroxaban Drugs Revenue by Region: 2019-2024

3.3.2 Global Rivaroxaban Drugs Revenue by Region: 2025-2030

3.4 North America Rivaroxaban Drugs Market Facts & Figures by Country

3.4.1 North America Rivaroxaban Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Rivaroxaban Drugs Sales by Country (2019-2030)

3.4.3 North America Rivaroxaban Drugs Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Rivaroxaban Drugs Market Facts & Figures by Country

3.5.1 Europe Rivaroxaban Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Rivaroxaban Drugs Sales by Country (2019-2030)

3.5.3 Europe Rivaroxaban Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Rivaroxaban Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Rivaroxaban Drugs Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Rivaroxaban Drugs Sales by Region (2019-2030)

3.6.3 Asia Pacific Rivaroxaban Drugs Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Rivaroxaban Drugs Market Facts & Figures by Country

3.7.1 Latin America Rivaroxaban Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Rivaroxaban Drugs Sales by Country (2019-2030)

3.7.3 Latin America Rivaroxaban Drugs Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Rivaroxaban Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Rivaroxaban Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Rivaroxaban Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Rivaroxaban Drugs Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Rivaroxaban Drugs Sales by Type (2019-2030)

4.1.1 Global Rivaroxaban Drugs Sales by Type (2019-2024)

4.1.2 Global Rivaroxaban Drugs Sales by Type (2025-2030)

4.1.3 Global Rivaroxaban Drugs Sales Market Share by Type (2019-2030)

4.2 Global Rivaroxaban Drugs Revenue by Type (2019-2030)

4.2.1 Global Rivaroxaban Drugs Revenue by Type (2019-2024)

4.2.2 Global Rivaroxaban Drugs Revenue by Type (2025-2030)

4.2.3 Global Rivaroxaban Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Rivaroxaban Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Rivaroxaban Drugs Sales by Application (2019-2030)

5.1.1 Global Rivaroxaban Drugs Sales by Application (2019-2024)

5.1.2 Global Rivaroxaban Drugs Sales by Application (2025-2030)

5.1.3 Global Rivaroxaban Drugs Sales Market Share by Application (2019-2030)

5.2 Global Rivaroxaban Drugs Revenue by Application (2019-2030)

5.2.1 Global Rivaroxaban Drugs Revenue by Application (2019-2024)

5.2.2 Global Rivaroxaban Drugs Revenue by Application (2025-2030)

5.2.3 Global Rivaroxaban Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Rivaroxaban Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Janssen Pharmaceuticals

6.1.1 Janssen Pharmaceuticals Company Information

6.1.2 Janssen Pharmaceuticals Description and Business Overview

6.1.3 Janssen Pharmaceuticals Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Janssen Pharmaceuticals Rivaroxaban Drugs Product Portfolio

6.1.5 Janssen Pharmaceuticals Recent Developments/Updates

6.2 Bayer

6.2.1 Bayer Company Information

6.2.2 Bayer Description and Business Overview

6.2.3 Bayer Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Bayer Rivaroxaban Drugs Product Portfolio

6.2.5 Bayer Recent Developments/Updates

6.3 Mylan

6.3.1 Mylan Company Information

6.3.2 Mylan Description and Business Overview

6.3.3 Mylan Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Mylan Rivaroxaban Drugs Product Portfolio

6.3.5 Mylan Recent Developments/Updates

6.4 Zydus

6.4.1 Zydus Company Information

6.4.2 Zydus Description and Business Overview

6.4.3 Zydus Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Zydus Rivaroxaban Drugs Product Portfolio

6.4.5 Zydus Recent Developments/Updates

6.5 Lupin

6.5.1 Lupin Company Information

6.5.2 Lupin Description and Business Overview

6.5.3 Lupin Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Lupin Rivaroxaban Drugs Product Portfolio

6.5.5 Lupin Recent Developments/Updates

6.6 Natco Pharma

6.6.1 Natco Pharma Company Information

6.6.2 Natco Pharma Description and Business Overview

6.6.3 Natco Pharma Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Natco Pharma Rivaroxaban Drugs Product Portfolio

6.6.5 Natco Pharma Recent Developments/Updates

6.7 Shanghai Huilun Pharmaceutical

6.7.1 Shanghai Huilun Pharmaceutical Company Information

6.7.2 Shanghai Huilun Pharmaceutical Description and Business Overview

6.7.3 Shanghai Huilun Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Shanghai Huilun Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.7.5 Shanghai Huilun Pharmaceutical Recent Developments/Updates

6.8 Qilu Pharmaceutical

6.8.1 Qilu Pharmaceutical Company Information

6.8.2 Qilu Pharmaceutical Description and Business Overview

6.8.3 Qilu Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Qilu Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.8.5 Qilu Pharmaceutical Recent Developments/Updates

6.9 HEC Pharma

6.9.1 HEC Pharma Company Information

6.9.2 HEC Pharma Description and Business Overview

6.9.3 HEC Pharma Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 HEC Pharma Rivaroxaban Drugs Product Portfolio

6.9.5 HEC Pharma Recent Developments/Updates

6.10 Beijing SL Pharmaceutical

6.10.1 Beijing SL Pharmaceutical Company Information

6.10.2 Beijing SL Pharmaceutical Description and Business Overview

6.10.3 Beijing SL Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Beijing SL Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.10.5 Beijing SL Pharmaceutical Recent Developments/Updates

6.11 Huahai Pharmaceutical

6.11.1 Huahai Pharmaceutical Company Information

6.11.2 Huahai Pharmaceutical Description and Business Overview

6.11.3 Huahai Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Huahai Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.11.5 Huahai Pharmaceutical Recent Developments/Updates

6.12 Yangtze River Pharmaceutical

6.12.1 Yangtze River Pharmaceutical Company Information

6.12.2 Yangtze River Pharmaceutical Description and Business Overview

6.12.3 Yangtze River Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Yangtze River Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.12.5 Yangtze River Pharmaceutical Recent Developments/Updates

6.13 Fujian Cosunter Pharmaceutical

6.13.1 Fujian Cosunter Pharmaceutical Company Information

6.13.2 Fujian Cosunter Pharmaceutical Description and Business Overview

6.13.3 Fujian Cosunter Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Fujian Cosunter Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.13.5 Fujian Cosunter Pharmaceutical Recent Developments/Updates

6.14 Zhejiang Conba Pharmaceutical

6.14.1 Zhejiang Conba Pharmaceutical Company Information

6.14.2 Zhejiang Conba Pharmaceutical Description and Business Overview

6.14.3 Zhejiang Conba Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Zhejiang Conba Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.14.5 Zhejiang Conba Pharmaceutical Recent Developments/Updates

6.15 Beijing Baiao Pharmaceutical

6.15.1 Beijing Baiao Pharmaceutical Company Information

6.15.2 Beijing Baiao Pharmaceutical Description and Business Overview

6.15.3 Beijing Baiao Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Beijing Baiao Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.15.5 Beijing Baiao Pharmaceutical Recent Developments/Updates

6.16 Lunan Pharmaceutical

6.16.1 Lunan Pharmaceutical Company Information

6.16.2 Lunan Pharmaceutical Description and Business Overview

6.16.3 Lunan Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.16.4 Lunan Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.16.5 Lunan Pharmaceutical Recent Developments/Updates

6.17 Chia Tai Tianqing Pharmaceutical

6.17.1 Chia Tai Tianqing Pharmaceutical Company Information

6.17.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview

6.17.3 Chia Tai Tianqing Pharmaceutical Rivaroxaban Drugs Sales, Revenue and Gross Margin (2019-2024)

6.17.4 Chia Tai Tianqing Pharmaceutical Rivaroxaban Drugs Product Portfolio

6.17.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Rivaroxaban Drugs Industry Chain Analysis

7.2 Rivaroxaban Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Rivaroxaban Drugs Production Mode & Process

7.4 Rivaroxaban Drugs Sales and Marketing

7.4.1 Rivaroxaban Drugs Sales Channels

7.4.2 Rivaroxaban Drugs Distributors

7.5 Rivaroxaban Drugs Customers

8 Rivaroxaban Drugs Market Dynamics

8.1 Rivaroxaban Drugs Industry Trends

8.2 Rivaroxaban Drugs Market Drivers

8.3 Rivaroxaban Drugs Market Challenges

8.4 Rivaroxaban Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Janssen Pharmaceuticals

Shanghai Huilun Pharmaceutical

Qilu Pharmaceutical

HEC Pharma

Beijing SL Pharmaceutical

Huahai Pharmaceutical

Yangtze River Pharmaceutical

Fujian Cosunter Pharmaceutical

Zhejiang Conba Pharmaceutical

Beijing Baiao Pharmaceutical

Lunan Pharmaceutical

Chia Tai-Tianqing Pharmaceutical

List of Tables

Table 1. Global Rivaroxaban Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Rivaroxaban Drugs Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Rivaroxaban Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Rivaroxaban Drugs Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Rivaroxaban Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Rivaroxaban Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Rivaroxaban Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Rivaroxaban Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Rivaroxaban Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Rivaroxaban Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Rivaroxaban Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Rivaroxaban Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Rivaroxaban Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rivaroxaban Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Rivaroxaban Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Rivaroxaban Drugs Sales by Region (2019-2024) & (K Units)

Table 18. Global Rivaroxaban Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Rivaroxaban Drugs Sales by Region (2025-2030) & (K Units)

Table 20. Global Rivaroxaban Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Rivaroxaban Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Rivaroxaban Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Rivaroxaban Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Rivaroxaban Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Rivaroxaban Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Rivaroxaban Drugs Sales by Country (2019-2024) & (K Units)

Table 27. North America Rivaroxaban Drugs Sales by Country (2025-2030) & (K Units)

Table 28. North America Rivaroxaban Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Rivaroxaban Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Rivaroxaban Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Rivaroxaban Drugs Sales by Country (2019-2024) & (K Units)

Table 32. Europe Rivaroxaban Drugs Sales by Country (2025-2030) & (K Units)

Table 33. Europe Rivaroxaban Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Rivaroxaban Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Rivaroxaban Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Rivaroxaban Drugs Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Rivaroxaban Drugs Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Rivaroxaban Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Rivaroxaban Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Rivaroxaban Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Rivaroxaban Drugs Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Rivaroxaban Drugs Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Rivaroxaban Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Rivaroxaban Drugs Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Rivaroxaban Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Rivaroxaban Drugs Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Rivaroxaban Drugs Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Rivaroxaban Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Rivaroxaban Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Rivaroxaban Drugs Sales (K Units) by Type (2019-2024)

Table 51. Global Rivaroxaban Drugs Sales (K Units) by Type (2025-2030)

Table 52. Global Rivaroxaban Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Rivaroxaban Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Rivaroxaban Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Rivaroxaban Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Rivaroxaban Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Rivaroxaban Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Rivaroxaban Drugs Price (US$/Unit) by Type (2019-2024)

Table 59. Global Rivaroxaban Drugs Price (US$/Unit) by Type (2025-2030)

Table 60. Global Rivaroxaban Drugs Sales (K Units) by Application (2019-2024)

Table 61. Global Rivaroxaban Drugs Sales (K Units) by Application (2025-2030)

Table 62. Global Rivaroxaban Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Rivaroxaban Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Rivaroxaban Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Rivaroxaban Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Rivaroxaban Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Rivaroxaban Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Rivaroxaban Drugs Price (US$/Unit) by Application (2019-2024)

Table 69. Global Rivaroxaban Drugs Price (US$/Unit) by Application (2025-2030)

Table 70. Janssen Pharmaceuticals Company Information

Table 71. Janssen Pharmaceuticals Description and Business Overview

Table 72. Janssen Pharmaceuticals Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Janssen Pharmaceuticals Rivaroxaban Drugs Product

Table 74. Janssen Pharmaceuticals Recent Developments/Updates

Table 75. Bayer Company Information

Table 76. Bayer Description and Business Overview

Table 77. Bayer Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Bayer Rivaroxaban Drugs Product

Table 79. Bayer Recent Developments/Updates

Table 80. Mylan Company Information

Table 81. Mylan Description and Business Overview

Table 82. Mylan Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Mylan Rivaroxaban Drugs Product

Table 84. Mylan Recent Developments/Updates

Table 85. Zydus Company Information

Table 86. Zydus Description and Business Overview

Table 87. Zydus Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Zydus Rivaroxaban Drugs Product

Table 89. Zydus Recent Developments/Updates

Table 90. Lupin Company Information

Table 91. Lupin Description and Business Overview

Table 92. Lupin Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Lupin Rivaroxaban Drugs Product

Table 94. Lupin Recent Developments/Updates

Table 95. Natco Pharma Company Information

Table 96. Natco Pharma Description and Business Overview

Table 97. Natco Pharma Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Natco Pharma Rivaroxaban Drugs Product

Table 99. Natco Pharma Recent Developments/Updates

Table 100. Shanghai Huilun Pharmaceutical Company Information

Table 101. Shanghai Huilun Pharmaceutical Description and Business Overview

Table 102. Shanghai Huilun Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Shanghai Huilun Pharmaceutical Rivaroxaban Drugs Product

Table 104. Shanghai Huilun Pharmaceutical Recent Developments/Updates

Table 105. Qilu Pharmaceutical Company Information

Table 106. Qilu Pharmaceutical Description and Business Overview

Table 107. Qilu Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Qilu Pharmaceutical Rivaroxaban Drugs Product

Table 109. Qilu Pharmaceutical Recent Developments/Updates

Table 110. HEC Pharma Company Information

Table 111. HEC Pharma Description and Business Overview

Table 112. HEC Pharma Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. HEC Pharma Rivaroxaban Drugs Product

Table 114. HEC Pharma Recent Developments/Updates

Table 115. Beijing SL Pharmaceutical Company Information

Table 116. Beijing SL Pharmaceutical Description and Business Overview

Table 117. Beijing SL Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Beijing SL Pharmaceutical Rivaroxaban Drugs Product

Table 119. Beijing SL Pharmaceutical Recent Developments/Updates

Table 120. Huahai Pharmaceutical Company Information

Table 121. Huahai Pharmaceutical Description and Business Overview

Table 122. Huahai Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Huahai Pharmaceutical Rivaroxaban Drugs Product

Table 124. Huahai Pharmaceutical Recent Developments/Updates

Table 125. Yangtze River Pharmaceutical Company Information

Table 126. Yangtze River Pharmaceutical Description and Business Overview

Table 127. Yangtze River Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Yangtze River Pharmaceutical Rivaroxaban Drugs Product

Table 129. Yangtze River Pharmaceutical Recent Developments/Updates

Table 130. Fujian Cosunter Pharmaceutical Company Information

Table 131. Fujian Cosunter Pharmaceutical Description and Business Overview

Table 132. Fujian Cosunter Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Fujian Cosunter Pharmaceutical Rivaroxaban Drugs Product

Table 134. Fujian Cosunter Pharmaceutical Recent Developments/Updates

Table 135. Zhejiang Conba Pharmaceutical Company Information

Table 136. Zhejiang Conba Pharmaceutical Description and Business Overview

Table 137. Zhejiang Conba Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. Zhejiang Conba Pharmaceutical Rivaroxaban Drugs Product

Table 139. Zhejiang Conba Pharmaceutical Recent Developments/Updates

Table 140. Beijing Baiao Pharmaceutical Company Information

Table 141. Beijing Baiao Pharmaceutical Description and Business Overview

Table 142. Beijing Baiao Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 143. Beijing Baiao Pharmaceutical Rivaroxaban Drugs Product

Table 144. Beijing Baiao Pharmaceutical Recent Developments/Updates

Table 145. Lunan Pharmaceutical Company Information

Table 146. Lunan Pharmaceutical Description and Business Overview

Table 147. Lunan Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 148. Lunan Pharmaceutical Rivaroxaban Drugs Product

Table 149. Lunan Pharmaceutical Recent Developments/Updates

Table 150. Chia Tai Tianqing Pharmaceutical Company Information

Table 151. Chia Tai Tianqing Pharmaceutical Description and Business Overview

Table 152. Chia Tai Tianqing Pharmaceutical Rivaroxaban Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 153. Chia Tai Tianqing Pharmaceutical Rivaroxaban Drugs Product

Table 154. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

Table 155. Key Raw Materials Lists

Table 156. Raw Materials Key Suppliers Lists

Table 157. Rivaroxaban Drugs Distributors List

Table 158. Rivaroxaban Drugs Customers List

Table 159. Rivaroxaban Drugs Market Trends

Table 160. Rivaroxaban Drugs Market Drivers

Table 161. Rivaroxaban Drugs Market Challenges

Table 162. Rivaroxaban Drugs Market Restraints

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

Table 166. Authors List of This Report

List of Figures

Figure 1. Product Picture of Rivaroxaban Drugs

Figure 2. Global Rivaroxaban Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Rivaroxaban Drugs Market Share by Type: 2023 & 2030

Figure 4. Tablets Product Picture

Figure 5. Oral Suspension Product Picture

Figure 6. Global Rivaroxaban Drugs Market Value by Application (2024-2030) & (US$ Million)

Figure 7. Global Rivaroxaban Drugs Market Share by Application: 2023 & 2030

Figure 8. Deep Vein Thrombosis

Figure 9. Pulmonary Embolism

Figure 10. Atrial Fibrillation

Figure 11. Other

Figure 12. Global Rivaroxaban Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Rivaroxaban Drugs Market Size (2019-2030) & (US$ Million)

Figure 14. Global Rivaroxaban Drugs Sales (2019-2030) & (K Units)

Figure 15. Global Rivaroxaban Drugs Average Price (US$/Unit) & (2019-2030)

Figure 16. Rivaroxaban Drugs Report Years Considered

Figure 17. Rivaroxaban Drugs Sales Share by Manufacturers in 2023

Figure 18. Global Rivaroxaban Drugs Revenue Share by Manufacturers in 2023

Figure 19. Global 5 and 10 Largest Rivaroxaban Drugs Players: Market Share by Revenue in Rivaroxaban Drugs in 2023

Figure 20. Rivaroxaban Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 21. Global Rivaroxaban Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Rivaroxaban Drugs Sales Market Share by Country (2019-2030)

Figure 23. North America Rivaroxaban Drugs Revenue Market Share by Country (2019-2030)

Figure 24. United States Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Rivaroxaban Drugs Sales Market Share by Country (2019-2030)

Figure 27. Europe Rivaroxaban Drugs Revenue Market Share by Country (2019-2030)

Figure 28. Germany Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Rivaroxaban Drugs Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Rivaroxaban Drugs Revenue Market Share by Region (2019-2030)

Figure 35. China Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Rivaroxaban Drugs Sales Market Share by Country (2019-2030)

Figure 43. Mexico Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Colombia Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East and Africa Rivaroxaban Drugs Sales Market Share by Country (2019-2030)

Figure 48. Middle East and Africa Rivaroxaban Drugs Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Rivaroxaban Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Rivaroxaban Drugs by Type (2019-2030)

Figure 53. Global Revenue Market Share of Rivaroxaban Drugs by Type (2019-2030)

Figure 54. Global Rivaroxaban Drugs Price (US$/Unit) by Type (2019-2030)

Figure 55. Global Sales Market Share of Rivaroxaban Drugs by Application (2019-2030)

Figure 56. Global Revenue Market Share of Rivaroxaban Drugs by Application (2019-2030)

Figure 57. Global Rivaroxaban Drugs Price (US$/Unit) by Application (2019-2030)

Figure 58. Rivaroxaban Drugs Value Chain

Figure 59. Rivaroxaban Drugs Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions